Abstract:

Background: Breast cancer is the most common cancer found in women worldwide. In 2012, more than 50% of breast cancer patients in Cipto Mangunkusumo Hospital were advanced breast cancer patients. Stage 3 breast cancer patients have five years’ survival rate by 72%, while who’s in stage 4 only by 22% even after receiving adequate treatment. It is said that only CD105, which specifically describes the intratumoral angiogenesis occurrences. Methods: A retrospective cohort analytic data from patient medical records Dharmais Cancer Hospital from 2011-2014 were studied. A simple random sampling and obtained a total of 32 patients. Statistical analysis was performed using univariate and multivariate analysis SPSS version 17.0 and medcalc. Results: The expression between CD105 with the survival rate is: crude HR 1.724 (95% CI 0.693 to 4.288) p=0.241. The median survival of the CD105 positive group is higher than the negative group. The relationship between CD105 groups Luminal A, therapy, and metastasis, the group with negative CD105 expression had a higher survival rate. There was a significant relationship between CD105 and clinicopathologic of breast cancer patients from age and CD105 expression (p=0.034). 71.8% of patients with HER2 negative, has a negative CD105 as well, and 60% of subjects with HER2-positive, suggesting that CD105 expression was also positive. Conclusion: CD105 can not be used as a prognostic factor in patients with advanced stage breast cancer, high CD105 patients have a lower survival compared with low or negative CD105 patients, and CD105 expression correlated with age and PR.

Keywords: